Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does hemophilia protect against atherosclerosis? A case-control study.

Franca Bilora1, Ezio Zanon, Francesco Petrobelli

  • 1Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School, Padua, Italy. franca.bilora@sanita.padova.it

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|May 19, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Italian Patients Journey for Gene Therapy in Haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Real-world provider experiences with hemophilia A gene therapy: administration of valoctocogene roxaparvovec.

Research and practice in thrombosis and haemostasis·2026
Same author

Integrating Clinical, Functional, and Patient-Reported Outcomes in Haemophilia Care: A Delphi-Based Consensus on a New Monitoring Tool.

Journal of clinical medicine·2026
Same author

Advantages of FVIII-Extended Half-Life (Turoctocog Alfa Pegol) in the Management of Cardiac Surgery in a Patient with Mild Hemophilia A: A Case Report and Literature Review.

Hematology reports·2025
Same author

Joint health status in people with moderate hemophilia A: a cross-sectional multicenter study.

Research and practice in thrombosis and haemostasis·2025
Same author

FVIII half-life products: A real-world experience.

Thrombosis research·2025

Hemophilia carriers show reduced atherosclerosis. This study found fewer plaques and lower intima-media thickness (IMT) in hemophilia carriers compared to controls, suggesting a protective effect against this cardiovascular disease.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Vascular Biology

Background:

  • Atherosclerosis is a major cause of cardiovascular disease.
  • The role of hemophilia carriers in atherosclerosis development is not well understood.
  • Hemophilia is a genetic bleeding disorder affecting coagulation.

Purpose of the Study:

  • To investigate whether carriers of hemophilia are protected against the development of atherosclerosis.
  • To compare the prevalence and severity of atherosclerosis in hemophilia carriers versus age-matched controls.

Main Methods:

  • A case-control study involving 50 hemophilia carriers and 50 age-matched controls.
  • Assessment of atherosclerosis using echo-color Doppler in carotid, femoral, brachial arteries, and abdominal aorta.

Related Experiment Videos

  • Quantification of atherosclerotic plaques and measurement of intima-media thickness (IMT).

    • Main Results:

    • Fewer atherosclerotic plaques were observed in hemophilia carriers (12.0%) compared to controls (30.0%).
    • The mean intima-media thickness (IMT) was significantly lower in hemophilia carriers across all examined arterial districts.
    • Of the total plaques, 30% were in patients with decreased coagulation (hemophilia carriers) and 70% in controls.

    Conclusions:

    • Hemophilia carriers exhibit a reduced prevalence and severity of asymptomatic atherosclerosis.
    • The findings suggest a protective effect of hemophilia against the development of atherosclerosis.
    • Further research is warranted to elucidate the underlying mechanisms of this protective association.